BRIEF published on 02/10/2025 at 20:11, 1 month 27 days ago Merck KGaA Explores Acquisition of Springworks Therapeutics Pharmaceutical Industry Stock Exchange Merck KGaA Acquisition Talks Springworks Therapeutics
BRIEF published on 02/10/2025 at 20:11, 1 month 27 days ago Merck KGaA envisage l'acquisition de Springworks Therapeutics Bourse Industrie Pharmaceutique Merck KGaA Discussions Sur L'acquisition Thérapeutique Springworks
PRESS RELEASE published on 02/10/2025 at 20:06, 1 month 27 days ago EQS-Adhoc: Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition Merck KGaA confirms advanced discussions with Springworks Therapeutics, Inc. on potential acquisition. No binding agreement has been reached yet Acquisition Discussions Merck KGaA Confirmation Springworks Therapeutics
BRIEF published on 07/26/2024 at 18:55, 8 months 14 days ago Merck KGaA Reports Strong Q2, Raises 2024 Guidance Healthcare Financial Forecast Q2 Results Merck KGaA Electronics
BRIEF published on 07/26/2024 at 18:55, 8 months 14 days ago Merck KGaA annonce un deuxième trimestre solide et relève ses prévisions pour 2024 Électronique Prévisions Financières Soins De Santé Résultats Du Deuxième Trimestre Merck KGaA
PRESS RELEASE published on 07/26/2024 at 18:50, 8 months 14 days ago EQS-Adhoc: Merck KGaA: Strong 2nd Quarter, Guidance raised Merck KGaA reports strong 2nd Quarter results, raises guidance for fiscal 2024, projecting higher net sales, EBITDA, and EPS. Healthcare and Electronics drive performance Healthcare Guidance Merck KGaA Electronics 2nd Quarter
BRIEF published on 06/24/2024 at 19:05, 9 months 15 days ago Merck KGaA Discontinues Phase III Trials of Xevinapant in Head & Neck Cancer Clinical Trials Head And Neck Cancer Merck KGaA Phase III Trials Xevinapant
BRIEF published on 06/24/2024 at 19:05, 9 months 15 days ago Merck KGaA interrompt les essais de phase III du Xevinapant dans le traitement du cancer de la tête et du cou Essais Cliniques Cancer De La Tête Et Du Cou Merck KGaA Xevinapant Essais De Phase III
PRESS RELEASE published on 06/24/2024 at 19:00, 9 months 15 days ago EQS-Adhoc: Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued Merck KGaA discontinues phase III trials of xevinapant in locally advanced head & neck cancer after interim analysis results. Xevinapant is currently under clinical investigation Merck KGaA Phase III Trials Xevinapant Locally Advanced Head & Neck Cancer Clinical Investigation
PRESS RELEASE published on 10/11/2023 at 22:06, 1 year 5 months ago EMD Electronics Celebrates Opening of New Arizona Factory, Contributing to the State's Growing Semiconductor Industry
Published on 04/10/2025 at 09:30, 12 minutes ago Chow Tai Fook Jewellery Group Celebrates First Anniversary of Brand Transformation
Published on 04/10/2025 at 06:08, 3 hours 34 minutes ago Tocvan Commences Drilling at Gran Pilar Gold - Silver Project Continues Expansion Zone Drilling Along Northern Corridors
Published on 04/10/2025 at 02:30, 7 hours 12 minutes ago Star Copper Completes Non-Brokered Private Placement for Proceeds of $2,500,000
Published on 04/09/2025 at 23:30, 10 hours 12 minutes ago AirIQ Announces Major Customer Win Accelerating Growth in Recurring Revenue
Published on 04/10/2025 at 09:24, 17 minutes ago u-blox introduces ANNA-B5: Compact, powerful and secure Bluetooth® LE module
Published on 04/10/2025 at 09:07, 34 minutes ago Chow Tai Fook Jewellery Group Celebrates First Anniversary of Brand Transformation
Published on 04/10/2025 at 09:03, 38 minutes ago EQS-Adhoc: Ad-hoc: Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 2025 - for the first time more than EUR 10.7 million revenue in one month
Published on 04/10/2025 at 08:52, 50 minutes ago Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 – for the first time more than EUR 10.7 million revenue in one month
Published on 04/09/2025 at 18:59, 14 hours 42 minutes ago Description of the 2025-2026 Share Buyback Program
Published on 04/09/2025 at 18:59, 14 hours 42 minutes ago Descriptif du programme de rachat d'actions 2025-2026
Published on 04/09/2025 at 18:57, 14 hours 44 minutes ago Minutes of the Combined General Meeting held on April 9, 2025
Published on 04/09/2025 at 18:57, 14 hours 44 minutes ago Compte-rendu de l'Assemblée Générale Mixte du 9 avril 2025
Published on 04/09/2025 at 17:45, 15 hours 57 minutes ago COGELEC : Résultats annuels 2024 et Chiffre d’affaires du 1 er trimestre 2025.
